ADC 2018: CVD-REAL 2: SGLT2 Inhibitors Associated With Lower CV Risk vs Other Glucose-Lowering Drugs
The large-scale, real-world data reveal that the CV effects of SGLT2 inhibitors may extend across a large population of patients with type 2 diabetes.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.